Impact of immunogenicity on 2-year clinical outcomes in patients with moderate-to-severe Crohn's disease treated with subcutaneous infliximab: A post hoc analysis of the Phase 3 LIBERTY-CD study

被引：0
|
作者：
Sands, B. E. [1 ]
Colombel, J. F. [1 ]
Rubin, D. T. [2 ]
Schreiber, S. [3 ]
Siegel, C. A. [4 ]
Yarur, A. [5 ]
Danese, S. [6 ,7 ]
Kang, A. [8 ]
Kim, D. H. [8 ]
Lee, Y. N. [8 ]
Hanauer, S. B. [9 ]
机构：
[1] Dr Henry D Janowitz Div Gastroenterol, Icahn Sch Med Mt Sinai, New York, NY USA
[2] Univ Chicago Med, Inflammatory Bowel Dis Ctr, Chicago, IL USA
[3] Univ Hosp Schleswig Holstein, Dept Med 1, Kiel, Germany
[4] Dartmouth Hitchcock Inflammatory Bowel Dis Ctr, Dartmouth Hitchcock Med Ctr, Lebanon, NH USA
[5] F Widjaja Inflammatory Bowel Dis Inst, Cedars Sinai Med Ctr, Angeles, CA USA
[6] IRCCS San Raffaele Hosp, Milan, Italy
[7] Univ Vita Salute San Raffaele, Dept Gastroenterol, Milan, Italy
[8] Celltr Inc, Global Med Div, Incheon, South Korea
[9] Northwestern Univ, Feinberg Sch Med, Dept Med, Div Gastroenterol & Hepatol, Chicago, IL 60611 USA
来源：
JOURNAL OF CROHNS & COLITIS | 2025年 / 19卷
关键词：
D O I：
10.1093/ecco-jcc/jjae190.0812
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P0638
引用
收藏
页码：I1254 / I1256
页数：2
相关论文
共 50 条
  • [1] IMPACT OF IMMUNOGENICITY ON CLINICAL OUTCOMES IN PATIENTS WITH CROHN'S DISEASE RECEIVING MAINTENANCE TREATMENT WITH SUBCUTANEOUS INFLIXIMAB: A POST HOC ANALYSIS OF THE LIBERTY-CD STUDY
    Colombel, Jean Frederic
    Danese, Silvio
    Schreiber, Stefan
    Sands, Bruce E.
    Yarur, Andres
    Kim, Dong-Hyeon
    Lee, Young Nam
    Hanauer, Stephen B.
    GASTROENTEROLOGY, 2024, 166 (05) : S803 - S803
  • [2] Impact of immunogenicity on clinical outcomes in patients with Crohn's disease receiving maintenance treatment with subcutaneous infliximab: A post hoc analysis of the LIBERTY-CD study
    Colombel, J. F.
    Danese, S.
    Schreiber, S.
    Sands, B. E.
    Yarur, A.
    Kim, D. H.
    Lee, Y. N.
    Hanauer, S. B.
    JOURNAL OF CROHNS & COLITIS, 2024, 18 : I1604 - I1605
  • [3] SUPER-RESPONDERS IN PATIENTS WITH MODERATE-TO-SEVERE CROHN'S DISEASE TREATED WITH SUBCUTANEOUS INFLIXIMAB MAINTENANCE THERAPY: A POST HOC ANALYSIS OF THE LIBERTY-CD STUDY
    Schreiber, Stefan
    Sands, Bruce E.
    Hanauer, Stephen B.
    Danese, Silvio
    Loftus, Edward V.
    Jeong, Ae Lee
    Kim, Dong-Hyeon
    Lee, Young Nam
    Colombel, Jean Frederic
    GASTROENTEROLOGY, 2024, 166 (05) : S804 - S804
  • [4] Super-responders in patients with moderate-to-severe Crohn's disease treated with subcutaneous infliximab maintenance therapy: A post hoc analysis of the LIBERTY-CD study
    Schreiber, S. W.
    Sands, B. E.
    Hanauer, S. B.
    Danese, S.
    Loftus, E. V., Jr.
    Jeong, A. L.
    Kim, D. H.
    Lee, Y. N.
    Colombel, J. F.
    JOURNAL OF CROHNS & COLITIS, 2024, 18 : I1365 - I1366
  • [5] P0702 Efficacy of subcutaneous infliximab maintenance therapy according to disease location in patients with moderate-to-severe Crohn's disease: A post hoc analysis of the Phase 3 LIBERTY-CD study
    Schreiber, S. W.
    Colombel, J. F.
    Dubinsky, M. C.
    Sands, B. E.
    Abraham, B. P.
    Regueiro, M.
    Danese, S.
    Park, H.
    Kim, D. H.
    Lee, Y. N.
    Hanauer, S. B.
    JOURNAL OF CROHNS & COLITIS, 2025, 19 : I1372 - I1373
  • [6] Treatment of patients with moderate-to-severe Crohn's disease with subcutaneous infliximab leads to an endoscopic response across all segments of the colon and terminal ileum: A post hoc analysis of the LIBERTY-CD study
    Sands, B. E.
    Dubinsky, M. C.
    D'Haens, G.
    Schreiber, S.
    Danese, S.
    Hanauer, S. B.
    Kim, D. H.
    Lee, Y. N.
    Colombel, J. F.
    JOURNAL OF CROHNS & COLITIS, 2024, 18 : I1773 - I1774
  • [7] IMPACT OF BODY MASS INDEX ON CLINICAL OUTCOMES AND DRUG LEVELS IN PATIENTS WITH CROHN'S DISEASE RECEIVING MAINTENANCE TREATMENT WITH SUBCUTANEOUS INFLIXIMAB: A POST HOC ANALYSIS OF THE LIBERTY-CD STUDY
    Yarur, Andres
    Hanauer, Stephen B.
    Schreiber, Stefan
    Colombel, Jean Frederic
    Deepak, Parakkal
    Jeong, Ae Lee
    Kim, Dong-Hyeon
    Lee, Young Nam
    Danese, Silvio
    GASTROENTEROLOGY, 2024, 166 (05) : S798 - S799
  • [8] Impact of body mass index (BMI) on clinical outcomes and drug levels in patients with Crohn's disease receiving maintenance treatment with subcutaneous infliximab: A post hoc analysis of the LIBERTY-CD study
    Yarur, A.
    Hanauer, S. B.
    Schreiber, S.
    Colombel, J. F.
    Deepak, P.
    Jeong, A. L.
    Kim, D. H.
    Lee, Y. N.
    Danese, S.
    JOURNAL OF CROHNS & COLITIS, 2024, 18 : I1921 - I1922
  • [9] Endoscopic and histologic outcomes in patients with moderate-to-severe Ulcerative Colitis treated with infliximab: A post hoc analysis of the Phase 3 LIBERTY-UC study
    Colombel, J. F.
    Hanauer, S. B.
    Schreiber, S.
    Danese, S.
    Deepak, P.
    Horst, S. N.
    Jeong, A. L.
    Kim, D. H.
    Lee, Y. N.
    Sands, B. E.
    JOURNAL OF CROHNS & COLITIS, 2025, 19 : i78 - i79
  • [10] Time to clinical recapture after dose escalation of subcutaneous infliximab (CT-P13 SC) following loss of response: A post hoc analysis of the 2-year Phase 3 LIBERTY-CD & LIBERTY-UC trials
    Dubinsky, M. C.
    Schreiber, S.
    Yarur, A. J.
    Sands, B. E.
    Hanauer, S. B.
    Danese, S.
    Yu, H.
    Kim, D. H.
    Lee, Y. N.
    Colombel, J. F.
    JOURNAL OF CROHNS & COLITIS, 2025, 19 : I2087 - I2088
12345